Online citations, reference lists, and bibliographies.
← Back to Search

Meta-Analyses Of Therapies For Postmenopausal Osteoporosis

A. Cranney, P. Tugwell, G. Wells, A. Willan, Lauren Griffith, N. Zytaruk, V. Robinson, D. Black, Jonathan., B. Shea, G. Guyatt, Jonathan D. Adachi, B. Weaver, A. Papaioannou, V. H. Replacement, Joan Peterson, D. Henry
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
III. Risedronate Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Jonathan Adachi, MD; Bruce Weaver, MSc; Nicole Zytaruk, RN; Alexandra Papaioannou, MD; Vivian Robinson, MSc, Beverley Shea, BScN, MSc; George Wells, PhD; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group IV. Raloxifene Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Nicole Zytaruk, RN; Vivian Robinson, MSc; Bruce Weaver, MSc; Jonathan Adachi, MD; George Wells, PhD; Beverley Shea, BScN, MSc; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group
This paper references
10.1136/bmj.309.6964.1286
Systematic Reviews: Identifying relevant studies for systematic reviews
K. Dickersin (1994)
10.1016/S0140-6736(96)07088-2
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
D. Black (1996)
10.1001/JAMA.280.7.605
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
S. Hulley (1998)
10.1093/OXFORDJOURNALS.AJE.A116756
Population-based study of survival after osteoporotic fractures.
C. Cooper (1993)
10.1001/ARCHINTE.1996.00440130053006
Mortality Following Fractures in Older Women: The Study of Osteoporotic Fractures
W. Browner (1996)
10.1001/JAMA.282.7.637
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
B. Ettinger (1999)
10.1037/H0031619
Measuring nominal scale agreement among many raters.
J. Fleiss (1971)
10.1136/jamia.1994.95153434
Research Paper: Developing Optimal Search Strategies for Detecting Clinically Sound Studies in MEDLINE
R. B. Haynes (1994)
10.1056/NEJM198312013092204
Bias in treatment assignment in controlled clinical trials.
T. Chalmers (1983)
10.1016/S0140-6736(99)04149-5
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
D. Moher (1999)
10.1016/S0140-6736(98)01085-X
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?
D. Moher (1998)
10.1136/bmj.315.7109.635
Impact of covert duplicate publication on meta-analysis: a case study
M. Tramèr (1997)
10.1056/NEJM199207233270406
Cumulative meta-analysis of therapeutic trials for myocardial infarction.
J. Lau (1992)
10.1359/jbmr.1998.13.11.1747
Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial
E. Lufkin (1998)
10.1093/OXFORDJOURNALS.EPIREV.A036084
Meta-analysis: state-of-the-science.
K. Dickersin (1992)
10.1001/JAMA.273.5.408
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.
K. Schulz (1995)
10.2307/2982993
Publication bias : a problem in interpreting medical data
C. Begg (1988)
10.7326/0003-4819-116-1-78
A consumer's guide to subgroup analyses.
A. Oxman (1992)
10.7326/0003-4819-131-12-199912210-00007
The Medical Review Article Revisited: Has the Science Improved?
F. McAlister (1999)
10.1001/jama.272.17.1367
Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group.
A. D. Oxman (1994)
10.7326/0003-4819-127-7-199710010-00005
Selecting and Appraising Studies for a Systematic Review
M. Meade (1997)
10.7326/0003-4819-127-9-199711010-00008
Quantitative Synthesis in Systematic Reviews
J. Lau (1997)
10.7326/0003-4819-115-11-837
Which Fractures Are Associated with Low Appendicular Bone Mass in Elderly Women
D. Seeley (1991)
10.2307/2289186
Statistical Methods for Meta-Analysis
L. Hedges (1985)
10.1177/096228029300200202
Review papers : The statistical basis of meta-analysis
Jl Fleiss (1993)
10.1016/0091-7435(91)90006-P
Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆
M. J. Stampfer (1991)
10.1001/JAMA.285.15.2000
Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials.
P. Devereaux (2001)
10.7326/0003-4819-126-5-199703010-00006
Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions
D. Cook (1997)
10.1001/ARCHINTE.1989.00390110045010
Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women.
S. Cummings (1989)
10.1001/JAMA.1991.03470010097038
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.
S. Yusuf (1991)
10.1016/0197-2456(95)00134-4
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
A. Jadad (1996)
10.1007/s001980070075
Risk of Mortality Following Clinical Fractures
J. Cauley (2000)
10.1002/JBMR.5650090802
The diagnosis of osteoporosis
J. Kanis (1992)
10.1001/JAMA.1990.03440100097014
The existence of publication bias and risk factors for its occurrence.
K. Dickersin (1990)



This paper is referenced by
10.1016/S1138-3593(07)73947-3
Condicionantes de la efectividad de un tratamiento farmacológico en la osteoporosis. Adherencia y cumplimiento
J. M. Q. Gómez (2007)
10.3904/kjim.2011.26.2.168
Effects of D-003 (10 mg/day) on Bone Mineral Density of the Lumbar Spine and Femoral Neck in Postmenopausal Women: A Randomized, Double-Blinded Study
A. Ceballos (2011)
10.1007/BF03345373
Effects of neridronate treatment in elderly women with osteoporosis
T. Cascella (2005)
10.1007/s00198-013-2576-2
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis
Mina Tadrous (2013)
10.1016/J.SONCN.2006.11.006
Endocrine effects of breast cancer treatment.
C. Stricker (2007)
10.1016/j.csm.2012.03.010
Sport-specific biomechanics of spinal injuries in aesthetic athletes (dancers, gymnasts, and figure skaters).
P. d’Hemecourt (2012)
10.1038/ki.2012.227
Oral bisphosphonate use in the elderly is not associated with acute kidney injury.
A. Shih (2012)
10.1185/030079904X16768
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis
A. Sebba (2004)
10.1016/j.fertnstert.2009.05.093
Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
D. Archer (2009)
10.1210/jc.2013-1195
Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine.
R. Bouillon (2013)
10.1093/AJCN/87.1.175
Chocolate consumption and bone density in older women.
J. Hodgson (2008)
10.1007/978-1-4020-6686-3
Medical decisions, estrogen and aging
J. Schulkin (2007)
10.1016/J.BERH.2005.07.001
Setting up an osteoporosis fracture liaison service: background and potential outcomes.
S. Gallacher (2005)
10.1016/B978-0-12-374602-3.00039-0
Primary Hyperparathyroidism in Men
C. Marcocci (2010)
10.1016/J.ECL.2004.07.001
Bone health and aging: implications for menopause.
F. Mirza (2004)
10.1016/J.DET.2006.01.013
Osteoporosis in health and disease: a dermatologist's perspective.
Angela Lamb (2006)
10.1007/s00431-003-1298-4
The role of bisphosphonates in diseases of childhood
T. Srivastava (2003)
10.1016/j.joca.2011.01.008
Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover.
R. H. Nielsen (2011)
10.1007/s00198-005-1996-z
Clinical risk indices, prediction of osteoporosis, and prevention of fractures: diagnostic consequences and costs
C. Pongchaiyakul (2005)
10.1007/s10304-013-0550-x
Prävention der postmenopausalen Osteoporose
M. Birkhaeuser (2013)
10.1186/1471-2474-12-167
Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice
D. Eekman (2011)
10.1371/journal.pone.0048481
Use of Alendronate Sodium (Fosamax) to Ameliorate Osteoporosis in Renal Transplant Patients: A Case-Control Study
W. Huang (2012)
10.1007/s00774-011-0325-1
Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia
I. Gorai (2011)
10.1007/s00198-007-0421-1
Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures
S. Morin (2007)
10.1186/1471-2474-6-39
Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women
A. Sawka (2005)
10.1016/J.BERH.2005.06.007
Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
P. Sambrook (2005)
Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis.
E. Sewerynek (2009)
10.1016/J.MATURITAS.2006.06.009
The effect of hormone therapy on the health-related quality of life in elderly women.
S. Eviö (2007)
10.1007/s00223-015-9955-y
Unexplained High BMD in DXA-Scanned Patients is Generalized Throughout the Skeleton and Characterized by Thicker Cortical and Trabecular Bone
S. Lomholt (2015)
RELATIONSHIP BETWEEN SERUM LEPTIN AND ADIPONECTIN AND BONE MASS WITH ENERGY INTAKE AND NUTRIENTS IN 40-60 YEAR-OLD POSTMENOPAUSAL WOMEN
A. Motaghi (2008)
Protuoksidativna i protuupalna učinkovitost flavonoida u osteoporozi izazvanoj retinoičnom kiselinom u štakora
Johann Nemrava (2016)
10.4172/2153-2435.1000285
Monthly Risedronate for the Treatment of Postmenopausal Osteoporosis
J. Iwamoto (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar